Aiqin He

Nantong, 226300, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer.

Efficacy of bevacizumab maintenance therapy in advanced ovarian cancer.

Journal: African journal of reproductive health
Published: July 29, 2025

Sialyltransferase-related genes as predictive factors for therapeutic response and prognosis in cervical cancer.

Sialyltransferase-related genes as predictive factors for therapeutic response and prognosis in cervical cancer.

Journal: PeerJ
Published: March 14, 2025

IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.

IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.

Journal: Med (New York, N.Y.)
Published: October 22, 2024

Construction of artificial neural network (ANN) based on predictive value of prognostic nutritional index (PNI) and neutrophil-to-lymphocyte ratio (NLR) in patients with cervical squamous cell carcinoma.

Construction of artificial neural network (ANN) based on predictive value of prognostic nutritional index (PNI) and neutrophil-to-lymphocyte ratio (NLR) in patients with cervical squamous cell carcinoma.

Journal: Medicine
Published: April 05, 2024

Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.

Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.

Journal: Targeted oncology
Published: September 05, 2023

First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.

First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.

Journal: Journal of gynecologic oncology
Published: August 03, 2023

Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR.

Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR.

Journal: Histology and histopathology
Published: May 04, 2023

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study.

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study.

Journal: Drug design, development and therapy
Published: February 12, 2023

CRTC2 promotes paclitaxel resistance by inducing autophagy in ovarian cancer in part via the PI3K-AKT signaling axis.

CRTC2 promotes paclitaxel resistance by inducing autophagy in ovarian cancer in part via the PI3K-AKT signaling axis.

Journal: Journal of Cancer
Published: December 29, 2022

High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma.

High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma.

Journal: Medicine
Published: October 18, 2022

Identification and validation of novel biomarker TRIM8 related to cervical cancer.

Identification and validation of novel biomarker TRIM8 related to cervical cancer.

Journal: Frontiers in oncology
Published: July 24, 2022

Gab2 plays a carcinogenic role in ovarian cancer by regulating CrkII.

Gab2 plays a carcinogenic role in ovarian cancer by regulating CrkII.

Journal: Journal of ovarian research
Published: April 29, 2022
Showing 1-12 of 20

Last Updated: 09/26/2026